TD Securities reiterated their speculative buy rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research report report published on Wednesday. The firm currently has a C$4.50 price target on the stock.
PLI has been the topic of a number of other research reports. CIBC reduced their price target on ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th. Scotiabank reaffirmed an outperform rating and set a C$5.00 price objective on shares of ProMetic Life Sciences in a research report on Tuesday, August 16th. Finally, Royal Bank Of Canada reaffirmed an outperform rating on shares of ProMetic Life Sciences in a research report on Wednesday, June 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. ProMetic Life Sciences has an average rating of Buy and a consensus price target of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) opened at 2.89 on Wednesday. The company’s 50 day moving average price is $2.88 and its 200 day moving average price is $3.01. The company’s market cap is $1.75 billion. ProMetic Life Sciences has a 12 month low of $1.67 and a 12 month high of $3.62.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.